Could a vaccine stop cervical cancer from coming back?
NCT ID NCT02405221
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This early study tested the safety of a vaccine called TA-CIN in 15 people who had been treated for HPV16-related cervical cancer. The goal was to see if the vaccine could help the immune system fight any remaining cancer cells and prevent the cancer from returning. Participants received the vaccine as a shot in the arm or thigh, and researchers monitored for side effects and immune responses.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HPV16 ASSOCIATED CERVICAL CANCER are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Baltimore, Maryland, 21287, United States
-
Women & Infants Center, University of Alabama at Birmingham
Birmingham, Alabama, 35233, United States